First genome-wide association study on rocuronium dose requirements shows association with SLCO1A2.

ABSTRACT:

Background

Rocuronium, a common neuromuscular blocking agent, is mainly excreted unchanged in urine (10-25%) and bile (>70%). Age, sex, liver blood flow, smoking, medical conditions, and ethnic background can affect its pharmacological actions. However, reasons for the wide variation in rocuronium requirements are mostly unknown. We hypothesised that pharmacogenetic factors might explain part of the variation.

Methods

One thousand women undergoing surgery for breast cancer were studied. Anaesthesia was maintained with propofol (50-100 μg kg^-1 min^-1) and remifentanil (0.05-0.25 μg kg^-1 min^-1). Neuromuscular block was maintained with rocuronium to keep the train-of-four ratio at 0-10%. DNA was extracted from peripheral blood and geno

SUBMITTER: Ahlstrom S 

PROVIDER: S-EPMC8132880 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature